ArticleJournal of pharmacokinetics and pharmacodynamics2006
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
Article in Journal of pharmacokinetics and pharmacodynamics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Model-based meta-analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms.British journal of clinical pharmacology · 2020Pooled it
- Quantitative analysis of efficacy and associated factors of calcium intake on bone mineral density in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Pooled it
- Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.World journal of urology · 2020Trial
- Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.Journal of clinical pharmacology · 2016Trial
- Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.British journal of clinical pharmacology · 2012Trial
- Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.Pharmaceutical research · 2007Trial
- The Dark Matter of Levodopa Pharmacodynamics.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- A computational pharmacokinetic-pharmacodynamic framework for simulating and comparing individualized levodopa dosing in Parkinson's disease.Frontiers in pharmacology · 2026Article
- Striatal Dopamine Actions and Movement: Inferences from Parkinson Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Review
- An integrative model of Parkinson's disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression.Journal of pharmacokinetics and pharmacodynamics · 2021Article
- Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease.Frontiers in neurology · 2020Article
- Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer.Journal of Parkinson's disease · 2020Review
- Treatment response and disease progression.Translational and clinical pharmacology · 2019Review
- Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales.Pharmaceutical research · 2019Article
- Developing and validating Parkinson's disease subtypes and their motor and cognitive progression.Journal of neurology, neurosurgery, and psychiatry · 2018Article
- Conditioning Against the Pathology of Parkinson's disease.Conditioning medicine · 2018Article
- Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?Frontiers in neuroscience · 2018Review
- Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson's Disease Patients.Pharmaceutical research · 2017Article
- Pharmacokinetics of RytaryClinical pharmacokinetics · 2017Review
- The missing, the short, and the long: Levodopa responses and dopamine actions.Annals of neurology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
We have modelled the Unified Parkinson's Disease Rating Scale (UPDRS) scores collected in 800 subjects followed for 8 years. Newly diagnosed and previously untreated subjects were initially randomized to treatment with placebo, deprenyl, tocopherol or both and, when clinical disability required, received one or more dopaminergic agents (levodopa (carbidopa/levodopa), bromocriptine, or pergolide). Using models for disease progression and pharmacodynamic models for drug effects we have characterized the changes in UPDRS over time to determine the influence of the various drug treatments. We have confirmed and quantitated the relative symptomatic benefits of the dopaminergic agents and provide model-based evidence for slowing of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.